GLP-1 Receptor Structure

The glucagon-like peptide-1 receptor (GLP-1R) is a class B G-protein-coupled receptor (GPCR) that mediates the incretin effects of GLP-1 on insulin secretion, gastric motility, and appetite regulation. High-resolution structural determination has transformed understanding of receptor pharmacology and enabled rational drug design.

Cryo-EM Structural Determination

Cryogenic electron microscopy (cryo-EM) has yielded structures of GLP-1R in complex with GLP-1, peptide agonists, and small-molecule agonists at resolutions between 2.5 and 3.2 Angstroms. The receptor comprises an extracellular domain (ECD), seven transmembrane helices (TM1-TM7), and three extracellular loops. GLP-1 binds in an extended conformation with its N-terminus inserting into the transmembrane core while the C-terminus contacts the ECD. A critical salt bridge between GLP-1 Arginine-36 and the receptor Aspartic acid at position 2.50 stabilizes the active-state conformation.

Receptor Activation Mechanism

GLP-1 binding triggers outward movement of transmembrane helix 6, creating a cavity on the intracellular surface that accommodates the G-alpha-s protein. The ECD acts as a lid that clamps down on the bound peptide, with conformational changes propagating through a network of conserved residues spanning the extracellular and transmembrane domains. Molecular dynamics simulations reveal that receptor activation involves sequential helix movements rather than a single concerted transition.

Biased Signaling

GLP-1R couples to multiple intracellular effectors including G-alpha-s, beta-arrestin 1, and beta-arrestin 2. Structural studies demonstrate that different ligands stabilize distinct receptor conformations that preferentially engage specific signaling pathways. Semaglutide and exenatide exhibit differing beta-arrestin recruitment profiles despite both acting as full G-alpha-s agonists. Biased agonism toward G-alpha-s over beta-arrestin may reduce desensitization and sustain therapeutic efficacy.

Allosteric Modulation

Negative allosteric modulators bind within the transmembrane domain to reduce GLP-1 binding affinity. Positive allosteric modulators may enhance receptor sensitivity to endogenous GLP-1, offering therapeutic potential in patients with reduced incretin responses.

Structural Basis for Drug Design

Atomic-level understanding of GLP-1R pharmacology has facilitated design of long-acting peptide agonists, small-molecule agonists, and dual incretin receptor agonists with optimized receptor engagement profiles.